Critical Pharmacodynamic Warning
carvedilol affects the 2D6 metabolic pathway.
When patients take carvedilol concurrently with drugs metabolized by 2D6, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.
Clinical Impact: As a strong inhibitor , carvedilol can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.
Clinical Overview for carvedilol
This page outlines known interaction pathways involving carvedilol, focusing primarily on its profile as a Strong inhibitor affecting the 2D6 pathway.
Enzyme Interaction Profile
carvedilol demonstrates strong inhibitor potency against 2D6. Clinical significance of this interaction requires further evaluation.
Inhibitor
A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.
Clinical Example: carvedilol affects 2D6Inducer
A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.
Interaction Details
| Drug Name | carvedilol |
| Affected Enzyme | 2D6 |
| Inhibitor Strength | Strong inhibitor Unknown |
| Inducers | No inducers listed |
| Inhibitors | fluoxetine |
Clinical Recommendations
Consult primary literature for guidance.
- Therapeutic drug levels
- Adverse effect monitoring
- Clinical response assessment
- Consider dose reduction
- Evaluate alternative therapies
- Adjust based on response
Quick Facts
4874
2D6
Enzyme Inhibition
Unknown
Clinical Significance
Clinical significance requires further evaluation.
Information Sources
- FDA Drug Interaction Database
- Clinical Pharmacology Guidelines
- Pharmaceutical Labeling Information
- Published Clinical Studies
Last updated: June 12, 2026